Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
14.08
-0.24 (-1.68%)
Oct 2, 2026, 4:00 PM EDT - Market closed
Mesoblast Employees
Mesoblast had 108 employees as of June 30, 2026. The number of employees increased by 27 or 33.33% compared to the previous year.
Employees
108
Change (1Y)
27
Growth (1Y)
33.33%
Revenue / Employee
$1,113,426
Profits / Employee
-$532,407
Market Cap
1.84B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 108 | 27 | 33.33% |
| Jun 30, 2025 | 81 | 8 | 10.96% |
| Jun 30, 2024 | 73 | -10 | -12.05% |
| Jun 30, 2023 | 83 | 6 | 7.79% |
| Jun 30, 2022 | 77 | -6 | -7.23% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Sarepta Therapeutics | 835 |
| Agios Pharmaceuticals | 540 |
| Vir Biotechnology | 367 |
| Nuvation Bio | 305 |
| Xencor | 260 |
| Zymeworks | 231 |
| Lakefront Biotherapeutics NV | 196 |
MESO News
- 8 days ago - Mesoblast receives FDA approval for potency assay to release Ryoncil product - TheFly
- 8 days ago - Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product - GlobeNewsWire
- 5 weeks ago - Mesoblast price target raised to $39 from $35 at Piper Sandler - TheFly
- 5 weeks ago - Full Year 2026 Mesoblast Limited Earnings Presentation Transcript - GuruFocus
- 5 weeks ago - Mesoblast Reports Substantial Revenue Growth to US$120M - GlobeNewsWire
- 5 weeks ago - Mesoblast H2 Earnings Call Highlights - MarketBeat
- 5 weeks ago - Mesoblast Earnings Call Transcript: H2 2026 - Transcripts
- 5 weeks ago - Mesoblast Annual report: H2 2026 - Filings